Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

(Bloomberg) -- Wegovy, the blockbuster weight-loss medication from Novo Nordisk A/S, eased heart failure symptoms for patients with diabetes in the latest large trial to support use of the drug to ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.